AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. - Wikidata - wikimedia - TriplyDB

AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.

AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.

http://www.wikidata.org/entity/Q33762738

about

Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells Incomplete radiofrequency ablation enhances invasiveness and metastasis of residual cancer of hepatocellular carcinoma cell HCCLM3 via activating β-catenin signaling High levels of the adhesion molecule CD44 on leukemic cells generate acute myeloid leukemia relapse after withdrawal of the initial transforming event Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of marrow maturation.Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.A novel melting curve-based method for detecting c-kit mutations in acute myeloid leukemia.Transcriptional repression of the Neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein.The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice.A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth.Nanoliter multiplex PCR arrays on a SlipChip.Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias CTHRC1 is upregulated by promoter demethylation and transforming growth factor-β1 and may be associated with metastasis in human gastric cancer.Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits Role of the erythropoietin receptor in ETV6/RUNX1-positive acute lymphoblastic leukemia.C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts.Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma Mastocytosis: state of the art.Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.In vivo and in vitro effects of heme oxygenase-1 silencing on the survival of acute myelocytic leukemia-M2 cells.Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.TRAPPC4-ERK2 interaction activates ERK1/2, modulates its nuclear localization and regulates proliferation and apoptosis of colorectal cancer cells High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia.Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling.Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo.Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells.Inhibition of DNA methyltransferase induces G2 cell cycle arrest and apoptosis in human colorectal cancer cells via inhibition of JAK2/STAT3/STAT5 signalling.Acute myeloid leukemia stem cells and CD33-targeted immunotherapy Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-β in acute myeloid leukemia Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia.Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.Acute promyelocytic leukemia: a model of molecular target based therapy.Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells.Skp1 in lung cancer: clinical significance and therapeutic efficacy of its small molecule inhibitors Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia

P2860

Q26740953-CA68DBB8-02E9-4FCB-93B0-D8540DB7D310 Q27318569-6C1F96F0-DCB1-49B6-B0C8-F942BEE8FC63 Q28299462-F20DD4D0-72E7-49E2-B1EA-40B60931D732 Q28478368-C740512C-12D7-4E7E-96F8-3551A9D5DAA2 Q28751687-753A2518-DD34-4B66-93C1-8F49DDCDFBEC Q30441475-7549F173-8562-4AC7-89C8-C7DED85D0605 Q33754603-BDC63A4C-742B-481C-AC2D-3059CC1363A8 Q33778329-05486105-C197-4F21-B9FF-C08798B45F7A Q33884193-39FD78E4-343A-4729-88B7-AB22BB0E8159 Q33895709-516BB118-2F3F-4361-B4E4-648DA1AA5FA8 Q34028454-F117F2FC-E733-4B82-A55D-06B4CD7E9178 Q34046793-0757E5C6-F63B-49E9-A8C7-F152154F3177 Q34169601-2142C4C1-7C47-46F5-B29C-C9E10C9C77D3 Q34275314-51EB5940-B654-446C-9E18-2C2E14F24B13 Q34300594-24A14DAF-31EF-48FE-A702-1FDB5C897021 Q34326017-E2632104-526A-45CE-B2C4-489788D45358 Q34572894-B3303AC0-A215-4F09-A84E-087707803817 Q34578418-0876D567-C757-43F2-8677-2C8B6E6E79D6 Q34586486-91AE8CE3-49D5-4F55-91F0-75B1DC20227C Q34641105-D442DDD1-ACAD-46DB-B627-1C88A930CE10 Q34663691-175F139D-76E0-45FC-BB91-8761E1B33B60 Q34664111-6BFE2F02-9AE4-46A9-B2DD-689D655E4AD6 Q35048614-A4EF1BF1-AD7B-4B17-8AFD-43254622D643 Q35051746-61B5A210-BD91-4E23-8D1C-8019595C14F9 Q35145910-65BBF3FC-A7C2-4F31-B2FD-3EF37BEE3A5D Q35361598-6A9E7F25-BE99-4467-8915-3FE2F819827C Q35641644-AA8E68FB-AF3D-4E9E-B2A9-ED75293334C8 Q35751083-DE2E2E2D-4E72-45EE-B8C4-58B9940B95EC Q35774096-85501C9C-67F0-4F6E-9879-89B864171048 Q35776442-232BBFF5-6E01-4739-B1F7-4E49139DF8C2 Q35786902-FC94322F-42ED-4601-8344-2989BE0894D0 Q35893359-5DE3F260-744B-4287-B479-0498E09C9D4A Q36058588-8660EFAC-EE13-4D6D-B93D-CE8D055F2CF4 Q36075913-5A8FFA13-0126-4696-83DA-591A0E5A6AD5 Q36152664-E4D85711-2DDC-41A6-AA58-6465C36E4C8B Q36166902-875308E2-D372-4642-B91A-08B8036169CE Q36270144-FC52A405-9CF2-4A6C-BA43-AD8D8B3869A8 Q36485302-B36CD79B-6349-4538-9A08-49FA9D2B0C4A Q36544267-9D6195E4-243F-4507-8259-F2F7B5AA4227 Q36548080-AEC30856-B738-4EAE-A086-0B5AA3607D98

P2860

AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.

http://www.wikidata.org/entity/Q33762738

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

AML1-ETO and C-KIT mutation/ov ...... nesis and response to Gleevec.

@ast

AML1-ETO and C-KIT mutation/ov ...... nesis and response to Gleevec.

@en

type

label

AML1-ETO and C-KIT mutation/ov ...... nesis and response to Gleevec.

@ast

AML1-ETO and C-KIT mutation/ov ...... nesis and response to Gleevec.

@en

prefLabel

AML1-ETO and C-KIT mutation/ov ...... nesis and response to Gleevec.

@ast

AML1-ETO and C-KIT mutation/ov ...... nesis and response to Gleevec.

@en

P1433

Q33762738-346948D4-EE14-4806-9515-F69B29087B4B

P1476

Q33762738-421690A7-80D3-4666-87D3-8F9080D7E641

P2093

Q33762738-031E2537-4B18-4833-8ABA-4EEE977B3EC2

Q33762738-0F62941F-613F-403C-817B-2E1BCC3525E8

Q33762738-0F95EDD9-EBC6-43BC-B105-39CD2B4B1F5D

Q33762738-1E0A827F-ECCA-4774-9839-F2DBF12359AF

Q33762738-2E679361-210E-467C-8461-39ED420B3294

Q33762738-3CD2B9E2-0793-4909-BB1E-E8ED14A808F3

Q33762738-65397FAD-9B73-4078-94A6-7DBF40C3D3D2

Q33762738-71BB35D2-F609-4151-A3A6-8ED57865E34D

Q33762738-76F091E1-4C6A-44B5-86EB-D307180779F9

Q33762738-833F9910-CDF5-4B3C-BAE1-CCD7C6215FA5

P2860

Q33762738-09DCDB0A-961F-4066-9C9D-C3FD8D9D86AE

Q33762738-12154AD3-E144-4BC5-A94B-B29DDBF63A63

Q33762738-1238B630-EF14-43CA-B57F-0F04EE4386FB

Q33762738-13EC565F-1595-43D1-9D12-043E4A2D1596

Q33762738-1AC71CF5-BE52-45DE-A63D-09DE89C48E82

Q33762738-1D94530B-76D5-441C-B861-452AEF0B540F

Q33762738-1DAA8F19-A5A7-4A13-A0AB-BED465732188

Q33762738-21160B5C-4555-4750-BC5E-92DE31C5C7F8

Q33762738-23FD1470-EE69-468D-9C1F-6CB0E779FC20

Q33762738-24A64E0E-8029-47C3-BB93-BBAC65BCD365

P304

Q33762738-0E551B3B-3B5D-44E9-B1C4-F60851210D6A

P31

Q33762738-B1A4B05A-67F0-466F-8CF9-E17F6AB0E458

P356

Q33762738-CF78AEF9-95A8-4389-B002-407527FB5647

P407

Q33762738-E934648D-54DC-47B6-9D89-0AD10AFD865D

P433

Q33762738-880865BC-70F0-4C17-90E7-E95EABA46912

P478

Q33762738-C5CC8843-F30E-4EF9-97E2-64C7BB5CF621

P50

Q33762738-B42D27D2-96B8-47AF-BDE8-4217D80B2ED5

Q33762738-C6B7ED3D-E87F-4BC6-9153-F150EEB0BB10

Q33762738-E5692BE1-F22E-4A13-9D1E-19A660637787

P577

Q33762738-89690B1A-7D31-4C7B-B323-3E15F4AD0B5E

P5875

Q33762738-3E92A6F0-E64C-41CA-A948-8A5D059AA23F

P698

Q33762738-6DEE5FFC-7C84-4595-9AA7-AA8F7D0C4277

P921

Q33762738-06BF65AF-2030-4045-89AC-174A08FBD558

Q33762738-F996ABB2-91EC-46DA-BA98-25E7FE156BA1

P932

Q33762738-33A84540-CD47-4EFB-966F-4F07B012F7CA

P356

PNAS.0408831102

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

AML1-ETO and C-KIT mutation/ov ...... enesis and response to Gleevec

@en

P2093

Bing Chen

http://www.w3.org/2001/XMLSchema#string

Feng Xu

http://www.w3.org/2001/XMLSchema#string

Guang Yang

http://www.w3.org/2001/XMLSchema#string

Guo-Qiang Chen

http://www.w3.org/2001/XMLSchema#string

Jian-Hua You

http://www.w3.org/2001/XMLSchema#string

Jing-Yi Shi

http://www.w3.org/2001/XMLSchema#string

Jue Chen

http://www.w3.org/2001/XMLSchema#string

Sai-Juan Chen

http://www.w3.org/2001/XMLSchema#string

Shu-Min Xiong

http://www.w3.org/2001/XMLSchema#string

Tong Yin

http://www.w3.org/2001/XMLSchema#string

P2860

Functional and physical interactions between AML1 proteins and an ETS protein, MEF: implications for the pathogenesis of t(8;21)-positive leukemias

ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain

Oncogenic kinase signalling

Stopped-flow kinetics of locked nucleic acid (LNA)-oligonucleotide duplex formation: studies of LNA-DNA and DNA-DNA interactions

Inducible chromosomal translocation of AML1 and ETO genes through Cre/loxP-mediated recombination in the mouse.

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations

Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation

Polymorphism ratio sequencing: a new approach for single nucleotide polymorphism discovery and genotyping.

Class III receptor tyrosine kinases: role in leukaemogenesis.

P304

1104-1109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0408831102

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-01-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8081450

http://www.w3.org/2001/XMLSchema#string

P698

15650049

http://www.w3.org/2001/XMLSchema#string

P921

P932

545849

http://www.w3.org/2001/XMLSchema#string